tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Seizures D012640 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Atherosclerosis D050197 85 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Leukemia D007938 74 associated lipids
Hyperlipidemias D006949 73 associated lipids
Melanoma D008545 69 associated lipids
Colitis D003092 69 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Reperfusion Injury D015427 65 associated lipids
Pain D010146 64 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Weight Loss D015431 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Nerve Degeneration D009410 53 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Osteosarcoma D012516 50 associated lipids
Thrombosis D013927 49 associated lipids
Fatty Liver D005234 48 associated lipids
Precancerous Conditions D011230 48 associated lipids
Psoriasis D011565 47 associated lipids
Leukemia P388 D007941 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Hyperalgesia D006930 42 associated lipids
Hypotension D007022 41 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Kim SK et al. Inflammatory mimetic microfluidic chip by immobilization of cell adhesion molecules for T cell adhesion. 2012 Analyst pmid:22822477
Menotta M et al. Label-free quantification of Tacrolimus in biological samples by atomic force microscopy. 2015 Anal. Chim. Acta pmid:26073814
Gómez-Ríos GA et al. Rapid determination of immunosuppressive drug concentrations in whole blood by coated blade spray-tandem mass spectrometry (CBS-MS/MS). 2018 Anal. Chim. Acta pmid:29254576
Wada A et al. Ribosome display and photo-cross-linking techniques for in vitro identification of target proteins of bioactive small molecules. 2014 Anal. Chem. pmid:24380432
Hopper JT and Oldham NJ Alkali metal cation-induced destabilization of gas-phase protein-ligand complexes: consequences and prevention. 2011 Anal. Chem. pmid:21863818
Sage L Fishing for MAGIC targets. 2005 Anal. Chem. pmid:16285140
Murakami Y et al. On-chip micro-flow polystyrene bead-based immunoassay for quantitative detection of tacrolimus (FK506). 2004 Anal. Biochem. pmid:15464959
Sellar KJ et al. Spectrophotometric assay for calcineurin activity in leukocytes isolated from human blood. 2006 Anal. Biochem. pmid:16979577
Cañadas O et al. Equilibrium studies of a fluorescent tacrolimus binding to surfactant protein A. 2005 Anal. Biochem. pmid:15802130
Carreras CW et al. An FKBP12 binding assay based upon biotinylated FKBP12. 2001 Anal. Biochem. pmid:11673895
Ahn SC et al. A tactic for screening inhibitors of interleukin-2 production. 2002 Anal. Biochem. pmid:12018952
Park JW et al. Liquid chromatography-mass spectrometry characterization of FK506 biosynthetic intermediates in Streptomyces clavuligerus KCTC 10561BP. 2009 Anal. Biochem. pmid:19539594
Sonatore LM et al. The utility of FK506-binding protein as a fusion partner in scintillation proximity assays: application to SH2 domains. 1996 Anal. Biochem. pmid:8811923
Blanchet B et al. Determination of serine/threonine protein phosphatase type 2B PP2B in lymphocytes by HPLC. 2003 Anal. Biochem. pmid:12479828
Ohtsu Y et al. Selective ligand purification using high-performance affinity beads. 2005 Anal. Biochem. pmid:15745744
Rupprecht KR et al. Development of a dot-blot assay for screening monoclonal antibodies to low-molecular-mass drugs. 2010 Anal. Biochem. pmid:20696124
Nozaki K et al. Elimination technique for alkali metal ion adducts from an electrospray ionization process using an on-line ion suppressor. 2010 Anal Sci pmid:20543506
den Burger JC et al. Analysis of cyclosporin A, tacrolimus, sirolimus, and everolimus in dried blood spot samples using liquid chromatography tandem mass spectrometry. 2012 Anal Bioanal Chem pmid:22899246
Neu V et al. On-line solid-phase extraction high-performance liquid chromatography-tandem mass spectrometry for the quantitative analysis of tacrolimus in whole blood hemolyzate. 2012 Anal Bioanal Chem pmid:22797715
Takahashi T et al. Isolating the whole complex of target proteins of FK506 using affinity resins from novel solid phases. 2006 Anal Bioanal Chem pmid:16601955
Tomás ML [Immunosuppressive agents: side effects]. 1997 An R Acad Nac Med (Madr) pmid:9616947
Navas López VM et al. [Safety and efficacy of oral tacrolimus in the treatment of paediatric inflammatory bowel disease]. 2009 An Pediatr (Barc) pmid:19427822
Zahdi MR et al. Erosive pustular dermatosis of the scalp successfully treated with oral prednisone and topical tacrolimus. 2013 Sep-Oct An Bras Dermatol pmid:24173187
Delgado L et al. Zoon's plasma cell balanitis: a report of two cases treated with pimecrolimus. 2011 Jul-Aug An Bras Dermatol pmid:22068766
Viana Fde O et al. Acral lichen sclerosus et atrophicus--case report. 2011 Jul-Aug An Bras Dermatol pmid:22068779
Cakici O et al. Periorbital discoid lupus: a rare localization in a patient with systemic lupus erythematosus. An Bras Dermatol pmid:28300917
Lima RS et al. Granuloma faciale: a good therapeutic response with the use of topical tacrolimus. An Bras Dermatol pmid:26560220
Sisti A et al. Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review. 2016 An Bras Dermatol pmid:27192518
Tamler C et al. Tacrolimus 0,1% ointment in the treatment of vitiligo: a series of cases. 2011 Jan-Feb An Bras Dermatol pmid:21437550
Holmgren G et al. Successful pregnancies and fatherhood in familial amyloidotic polyneuropathy (FAP Val30Met) patients with liver transplantation. 2004 Amyloid pmid:15478469
Fix OK et al. Liver transplant alone without kidney transplant for fibrinogen Aα-chain (AFib) renal amyloidosis. 2016 Amyloid pmid:26972447
Kyles AE et al. Comparison of the in vitro antiproliferative effects of five immunosuppressive drugs on lymphocytes in whole blood from cats. 2000 Am. J. Vet. Res. pmid:10951980
Kyles AE et al. Pharmacokinetics of tacrolimus after multidose oral administration and efficacy in the prevention of allograft rejection in cats with renal transplants. 2003 Am. J. Vet. Res. pmid:12856780
Arango C et al. A 29-year-old renal transplant recipient with acute respiratory failure. 2012 Am. J. Trop. Med. Hyg. pmid:22665592
Spada M et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. 2006 Am. J. Transplant. pmid:16771811
Saliba F et al. Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial. 2017 Am. J. Transplant. pmid:28133906
de Fijter JW et al. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. 2017 Am. J. Transplant. pmid:28027625
Singh K et al. Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. 2014 Am. J. Transplant. pmid:25359003
Dugast E et al. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. 2016 Am. J. Transplant. pmid:27367750
Tang Q Pharmacokinetics of therapeutic Tregs. 2014 Am. J. Transplant. pmid:25358900
Trofe-Clark J et al. Immunosuppression, generic drugs and the FDA. 2012 Am. J. Transplant. pmid:22176626
Latran M Response to Klintmalm on the use of generic immunosuppression. 2012 Am. J. Transplant. pmid:22176636
Ellis CL and Racusen LC Mild rise in creatinine six months post kidney transplant. 2012 Am. J. Transplant. pmid:22845913
Krenzien F et al. Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus. 2017 Am. J. Transplant. pmid:27754593
Saikali JA et al. Sirolimus may promote thrombotic microangiopathy. 2003 Am. J. Transplant. pmid:12603218
Wang Q et al. Biodegradable microsphere-loaded tacrolimus enhanced the effect on mice islet allograft and reduced the adverse effect on insulin secretion. 2004 Am. J. Transplant. pmid:15084166
Schubert M et al. Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. 2004 Am. J. Transplant. pmid:15084173
Borrows R et al. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. 2004 Am. J. Transplant. pmid:15476485
Hernández-Fisac I et al. Tacrolimus-induced diabetes in rats courses with suppressed insulin gene expression in pancreatic islets. 2007 Am. J. Transplant. pmid:17725683
Frassetto LA and Benet LZ Pharmacogenomics and transplantation: where are we? 2004 Am. J. Transplant. pmid:15147415
MacPhee IA et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. 2004 Am. J. Transplant. pmid:15147425
Artz MA et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. 2004 Am. J. Transplant. pmid:15147428
Hirsch HH et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. 2013 Am. J. Transplant. pmid:23137180
Mujtaba MA et al. Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. 2014 Am. J. Transplant. pmid:25179306
Koefoed-Nielsen PB et al. Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. 2002 Am. J. Transplant. pmid:12099520
Shihab FS et al. Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study. 2013 Am. J. Transplant. pmid:23167508
Alloway RR et al. A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. 2012 Am. J. Transplant. pmid:22759200
Wlodarczyk Z et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. 2009 Am. J. Transplant. pmid:19681813
Hesselink DA et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. 2005 Am. J. Transplant. pmid:15816878
Byrne GW et al. Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. 2005 Am. J. Transplant. pmid:15816881
Lucey MR et al. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. 2005 Am. J. Transplant. pmid:15816894
Pillebout E et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). 2005 Am. J. Transplant. pmid:15816895
Madariaga ML et al. Kidney-induced cardiac allograft tolerance in miniature swine is dependent on MHC-matching of donor cardiac and renal parenchyma. 2015 Am. J. Transplant. pmid:25824550
Vanrenterghem Y et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. 2005 Am. J. Transplant. pmid:15636615
Sindhi R et al. Enhanced donor-specific alloreactivity occurs independently of immunosuppression in children with early liver rejection. 2005 Am. J. Transplant. pmid:15636616
Shergill AK et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. 2005 Am. J. Transplant. pmid:15636619
Tydén G et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. 2005 Am. J. Transplant. pmid:15636623
Woodle ES et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. 2005 Am. J. Transplant. pmid:15636625
Mian AN et al. Mycoplasma hominis septic arthritis in a pediatric renal transplant recipient: case report and review of the literature. 2005 Am. J. Transplant. pmid:15636628
Gregoor PS and Weimar W Tacrolimus and pure red-cell aplasia. 2005 Am. J. Transplant. pmid:15636632
Tremblay S et al. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. 2017 Am. J. Transplant. pmid:27340950
Padiyar A et al. Clinical predictors of proteinuria after conversion to sirolimus in kidney transplant recipients. 2010 Am. J. Transplant. pmid:20055793
Hardinger KL et al. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. 2010 Am. J. Transplant. pmid:20055811
Bhorade SM et al. Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. 2003 Am. J. Transplant. pmid:14629288
Pondrom S The AJT report. 2008 Am. J. Transplant. pmid:18324976
Fan DM et al. Successful ABO-incompatible living-related intestinal transplantation: a 2-year follow-up. 2015 Am. J. Transplant. pmid:25808777
Okabayashi T et al. Mobilization of host stem cells enables long-term liver transplant acceptance in a strongly rejecting rat strain combination. 2011 Am. J. Transplant. pmid:21883903
Hellemons ME et al. Former smoking is a risk factor for chronic kidney disease after lung transplantation. 2011 Am. J. Transplant. pmid:21883906
Maes BD et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. 2002 Am. J. Transplant. pmid:12484345
Mazariegos GV et al. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. 2005 Am. J. Transplant. pmid:15643991
Knechtle SJ et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. 2009 Am. J. Transplant. pmid:19344431
Bahra M et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. 2005 Am. J. Transplant. pmid:15644002
Min SI et al. Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. 2013 Am. J. Transplant. pmid:23734831
Bunnapradist S et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. 2013 Am. J. Transplant. pmid:23279614
Ceschi A et al. Acute calcineurin inhibitor overdose: analysis of cases reported to a national poison center between 1995 and 2011. 2013 Am. J. Transplant. pmid:23279718
Kaplan B and Kirk AD Tacrolimus and sirolimus: when bad things happen to good drugs. 2006 Am. J. Transplant. pmid:16827845
Vanhove T et al. High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. 2016 Am. J. Transplant. pmid:27013142
Teuteberg JJ et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. 2010 Am. J. Transplant. pmid:19889126
Haufroid V et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. 2006 Am. J. Transplant. pmid:17049058
Shapiro R et al. Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation. 2007 Am. J. Transplant. pmid:17908272
Rush D et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. 2007 Am. J. Transplant. pmid:17908280
Turgut F and Akcay A Renal function estimation in cirrhosis. 2009 Am. J. Transplant. pmid:19519814
Irish WD et al. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. 2011 Am. J. Transplant. pmid:21564522
Tricot L et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. 2009 Am. J. Transplant. pmid:19519819
Friman S et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. 2011 Am. J. Transplant. pmid:21564523
Kofler S et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. 2009 Am. J. Transplant. pmid:19519820
Barbas AS et al. Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation. 2013 Am. J. Transplant. pmid:23331705
Gatault P et al. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. 2017 Am. J. Transplant. pmid:27862923
Margreiter R et al. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. 2008 Am. J. Transplant. pmid:18510632
Miller LW Cardiovascular toxicities of immunosuppressive agents. 2002 Am. J. Transplant. pmid:12392286